A randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate

Journal of Clinical Pharmacology

Volumn 44, Issue 12, 2004, Pages 1391-1397

  Madaras Kelly, Karl ^a,b   Michas, Patricia ^a   George, Molly ^a   May, Matthew P ^b   Adejare, Adeboye ^c  

^a Boise VA Medical Center   (United States)

^b IDAHO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Cephalexin; Drug interactions; Omeprazole; Pharmacokinetics; Ranitidine

Indexed keywords

CEFALEXIN; OMEPRAZOLE; RANITIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STEADY STATE; STREPTOCOCCUS PYOGENES;

ADULT; AREA UNDER CURVE; CEPHALEXIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OMEPRAZOLE; RANITIDINE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

EID: 8744260821     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004269558     Document Type: Article

References (16)

1. Derrick CW, Reilly K. The role of cephalexin in the treatment of skin and soft-tissue infections. Postgrad Med J. 1981;59(suppl 5):43-46.
2. Mallory SB. Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. Am J Med. 1991;91(3A):36S-39S.
3. Tack KJ, Littlejohn TW, Mailloux G, Walf MM, Keyserking CH. Cefdinir versus cephalexin for the treatment of skin and skin structure infections. The Cefdinir Adult Skin Infection Study Group. Clin Ther. 1998;20:244-256.
4. Karchmer AW. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995:247-264.
5. Bergan T, Midtvedt T, Erikssen J. Human pharmacokinetics of cephalexin. Pharmacology. 1970;4:264-272.
6. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992;36:2577-2583.
7. McNabb JJ, Khanh QB. B-Lactam pharmacodynamics. In: Nightingale CH, Murkawa T, Ambrose PG, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel Dekker; 2002:99-123.
8. Madaras-Kelly K, Arbogast RA, Jue SG. Review of the failure rate of cephalexin versus other antibiotics used to treat uncomplicated outpatient cellulitis. Pharmacotherapy. 2000;20:199-205.
9. Deppermann K, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother. 1989;33:1901-1907.
10. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657-680.
11. Jonkman JH, Reinberg A, Oosterhuis B, et al. Dosing time and sex-related differences in the pharmacokinetics of cefodizime and in the circadian cortisol rhythm. Chronobiologia. Jan-Jun 1988;15:89-102.
12. Maiza A, Dale-Yates PT. Variability in the renal clearance of cephalexin in experimental renal failure. J Phamracokinet Biopharm. 1993;21:19-30.
13. Van Crugten J, Bochner F, Keal J, Somogyi A. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans: studies with anionic, cationic, and zwitterionic drugs. J Pharmacol Exp Ther. 1986;236:481-487.
14. Snyder NJ, Tabas LB, Berry DM, Duckworth DC, Spry DO, Dantzig AH. Structure-activity relationships of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells. Antimicrob Agents Chemother. 1997;41:1649-1657.
15. Tamai I, Tomizawa N, Takeuchi T, Nakayama K, Higashida H, Tsuji A. Functional expression of transporter for B-lactam antibiotics and dipeptides in Exenopus laevis oocytes injected with messenger RNA from human, rat and rabbit small intestines. J Pharmcol Exp Ther. 1995;273:26-31.
16. Kumar A, Murray D, Hanna C, et al. Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections. Antimicrob Agents Chemother. 1988;32:882-885.